Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.

ABSTRACT:

SUBMITTER: Cheung LC 

PROVIDER: S-EPMC6601077 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature